ErbB2 / HER2 antibody. Suitable for Flow Cyt, ICC/IF, IHC-Fr and reacts with samples. Cited in 10 publications.
Images
Publications
Filter by
- Cancers 12:2020Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Oncolytic Virus.Applications:Unspecified applicationReactive species:Unspecified reactive speciesGuendalina Froechlich et. al.PubMed 33213060
- Frontiers in oncology 10:1912020miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines.Applications:Unspecified applicationReactive species:Unspecified reactive speciesLihi Ninio-Many,Elad Hikri,Tamar Burg-Golani,Salomon M Stemmer,Ruth Shalgi,Irit Ben-AharonPubMed 32185126
- Oncotarget 9:27736-277512018ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.Applications:Unspecified applicationReactive species:Unspecified reactive speciesKarineh Petrossian et. al.PubMed 29963233
- Human pathology 77:35-442018ACOT1 expression is associated with poor prognosis in gastric adenocarcinoma.
- Journal of immunology research 2017:39082892017A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies.Applications:Flow CytReactive species:HumanChristophe Lallemand,Feifei Liang,Flore Staub,Maud Simansour,Benoit Vallette,Lue Huang,Rosa Ferrando-Miguel,Michael G ToveyPubMed 29104875
- Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20:416-4272016PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYasunori Deguchi,Hiroshi Okabe,Nobu Oshima,Shigeo Hisamori,Sachiko Minamiguchi,Manabu Muto,Yoshiharu SakaiPubMed 27517839
- Molecular therapy : the journal of the American Society of Gene Therapy 22:1029-382014Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Applications:Unspecified applicationReactive species:Unspecified reactive speciesAnat Globerson-Levin,Tova Waks,Zelig EshharPubMed 24572294
- OncoTargets and therapy 6:693-7012013Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro?
- Molecular oncology 7:440-512013Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen.Applications:Unspecified applicationReactive species:Unspecified reactive speciesAndrew J McCluskey,Andrew J Olive,Michael N Starnbach,R John CollierPubMed 23290417
- Journal of immunology (Baltimore, Md. : 1950) 183:5563-742009A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.Applications:Flow CytReactive species:HumanYangbing Zhao,Qiong J Wang,Shicheng Yang,James N Kochenderfer,Zhili Zheng,Xiaosong Zhong,Michel Sadelain,Zelig Eshhar,Steven A Rosenberg,Richard A MorganPubMed 19843940
Key facts
- Storage buffer
pH: 7.2
Preservative: 0.02% Sodium azide
Constituents: 0.87% Sodium chloride, 0.328% Sodium phosphate- Form
Liquid
Reactivity data
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Flow Cyt | Reactivity Reacts | Dilution info - | Notes - |
Application ICC/IF | Reactivity Reacts | Dilution info - | Notes - |
Application IHC-Fr | Reactivity Reacts | Dilution info - | Notes Staining of paraffin embedded tissues is not recommended. AFFIBODY® MOLECULES ARE PROTOCOL SPECIFIC. PLEASE REFER TO THE "PROTOCOLS" LINKS BELOW. |
Associated Products
Select an associated product type
8 products for Alternative Product
Target data
Function
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
Alternative names
Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, MLN 19, ERBB2, NGL, NEU, MLN19, HER2
Recommended products
ErbB2 / HER2 antibody. Suitable for Flow Cyt, ICC/IF, IHC-Fr and reacts with samples. Cited in 10 publications.
Alternative names
Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, MLN 19, ERBB2, NGL, NEU, MLN19, HER2
Key facts
- Storage buffer
pH: 7.2
Preservative: 0.02% Sodium azide
Constituents: 0.87% Sodium chloride, 0.328% Sodium phosphate- Form
Liquid
- Concentration
- Purification notes
The purity of this product is >98% as determined by RP-HPLC analysis.
Storage
- Shipped at conditions
Blue Ice
- Appropriate short-term storage duration
1-2 weeks
- Appropriate short-term storage conditions
+4°C
- Appropriate long-term storage conditions
-20°C
- Aliquoting information
Upon delivery aliquot
Notes
This product is a recombinant protein produced in E.coli.
What are Affibody Molecules?
Affibody® affinity ligands are unique research reagents, produced using innovative protein-engineering technologies. They are small, simple proteins composed of a three-helix bundle based on the scaffold of one of the IgG-binding domains of Protein A. Protein A is a surface protein from the bacterium Staphylococcus aureus. This scaffold has excellent features as an affinity ligand and can be designed to bind with high affinity to any given target protein. The domain consists of 58 amino acids, 13 of which are randomized to generate Affibody® libraries with a large number of ligand variants. Thus, the libraries consist of a multitude of protein ligands with an identical backbone and variable surface-binding properties. In function, Affibody® Molecules mimic monoclonal antibodies. Compared to antibodies, the most striking dissimilarity of Affibody® Molecules is the small size. Affibody® Molecules have a molecular weight of 6kDa, compared to the molecular weight of antibodies, which is 150kDa. In spite of its small size, the binding site of Affibody® Molecules is similar to that of an antibody. The advantages of Affibody® Molcules over antibodies are: -their small size -the simple structure of the molecules -its robust physical properties; able to withstand a broad range of analytical conditions, including extreme pH and elevated temperature -its ability to fold correctly intracellularly -the fast and cost effective production in bacteria -the potential to couple Affibody® Molecules in multimeric constructs Affibody® Molecules have highly competitive properties for applications within affinity purification, sample preparation, protein detection and in vitro diagnostics.
Supplementary info
This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
The ErbB2 also known as HER2 or HER2 protein is a transmembrane receptor protein with a molecular weight of about 185 kDa. It serves as part of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. The ErbB2 protein is expressed mainly in epithelial tissues including those of the breast and the gastrointestinal tract. It lacks a known ligand-binding domain which sets it apart from other members of its family. Due to its structure ErbB2 dimerizes with other members of the EGFR family to exert its effects in cellular signaling.
- Biological function summary
The role of ErbB2 extends beyond a singular function. It becomes an active component when forming heterodimers with other EGFR family members such as ErbB3 to initiate various downstream signaling cascades. The dimerization activates intracellular pathways leading to cell proliferation survival differentiation and migration. Within cells ErbB2 influences processes critical for normal development and tissue homeostasis contributing significantly to signal transduction networks.
- Pathways
ErbB2 plays a pivotal role in pathways such as the PI3K/Akt and MAPK/ERK pathways. These pathways are important in mediating cellular responses to growth signals. The PI3K/Akt pathway activated by HER2 signaling regulates cell growth and survival while the MAPK/ERK pathway contributes to cell differentiation and proliferation. ErbB2's interaction with proteins like ErbB3 is fundamental in these pathways increasing the amplitude and diversity of downstream signals.
- Associated diseases and disorders
ErbB2 is significantly associated with breast cancer and gastric cancer. The overexpression or gene amplification of HER2 is observed in approximately 20% of breast cancer cases correlating with aggressive tumor growth and poor prognosis. ErbB2-related signaling contributes to oncogenic processes by promoting excessive cell proliferation. Targeting ErbB2 in these cancers is common using therapies such as monoclonal antibodies like trastuzumab. In the context of gastric cancer the role of ErbB2 mirrors its function in breast cancer and targeting HER2 holds therapeutic potential.
Product promise
Tested
We have tested this species and application combination and it works. It is covered by our product promise.
Expected
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
Predicted
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
Not recommended
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Immunocytochemistry/ Immunofluorescence - Anti-ErbB2 / HER2 Affibody® Molecule (FITC) (ab31891)
Human mammary gland cell line SK-BR3 cells were stained with fluorescin conjugated Anti-ErbB2 / HER2 Affibody® molecule (ab31891). The staining was localized to the membrane of the ErbB 2 expressing human mammary gland cells. Nuclei were counter stained with DAPI (blue fluorescence). The SK-BR3 cells were stained for 30 minutes at a concentration of 1-5ug Affibody® molecule/ml.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com